GPP
BLUE

Great Point Partners’s bluebird bio BLUE Stock Holding History

Great Point Partners’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-38,600
Closed -$21.6M – 41
2016
Q2 		$21.6M Buy
38,600
+8,250
+27% +$4.67M 6.2% 6
2016
Q1 		$16.7M Buy
+30,350
New +$18.6M 6% 6

Other funds holding BLUE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Great Point Partners's BLUE Position: Q3 2016 in Review

Great Point Partners sold out of bluebird bio (BLUE) in Q3 2016, closing a stake of 38,600 shares — an estimated $21.6M sold.

Great Point Partners first reported a position in BLUE in Q1 2016 and held it in 2 quarters. The position peaked at $21.6M in Q2 2016. 200 funds tracked by Wall St. Rank hold BLUE as of Q3 2016.

  • Great Point Partners reported no remaining bluebird bio position as of Q3 2016 after selling out during the quarter.
  • Great Point Partners sold 38,600 bluebird bio shares in Q3 2016, an estimated $21.6M.
  • Great Point Partners first reported a position in bluebird bio in Q1 2016 and held it in 2 quarters.
  • Great Point Partners's bluebird bio position peaked at $21.6M in Q2 2016.
  • 200 funds tracked by Wall St. Rank held bluebird bio as of Q3 2016.

Based on Great Point Partners's 13F filing for Q3 2016, filed 14 Nov 2016.